Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Nektar Therapeutics

NASDAQ: NKTR · Life Sciences · 5 alerts · CIK 906709

Share price
$36.44Close, Nov 16
Market cap
$1.25B
Shares outstanding
34.21MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nektar Therapeutics filings on SEC EDGAR ↗

7:59 AM ET 8-K
Clinical Trial Data

Nektar Therapeutics Clinical Trial Data

Nektar Therapeutics announced long-term Phase 2b data for rezpegaldesleukin in patients with alopecia areata (REZOLVE-AA) and atopic dermatitis (REZOLVE-AD) at the EADV Congress 2026. The data demonstrated sustained hair regrowth and deepening of response even six months after treatment cessation, suggesting a differentiated regulatory T cell (Treg) mechanism compared to existing systemic therapies.

Earnings call
Oct 1, 2026, 3:00 PM ET

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.